The long awaited Malaria Vaccine Latest News

No replies
admin's picture
Offline
Joined: 2010-12-22

The fact that Malaria is the Most Prevalent chronic infection is under estimated.

 

Malaria vaccine currently in development phase is envisaged to reduce Malaria incidence by 75% and would ultimately allow Malaria elimination altogether. The CDC and WHO have set 2030 as the Target for the Malaria vaccine Market availability.

                             

 

This new target comes in addition to the original 2006 Roadmap’s goal of having a licensed vaccine against Plasmodium falciparum malaria, the most deadly form of the disease, for children under Five years of age in Africa by 2015.

 

Unfortunately in spite  all the recent progress nations have made, and despite important innovations and Technology advancement  in diagnostics, drugs and vector control, the global burden of malaria remains unacceptably high.”

 

The most recent figures by the WHO indicate that malaria causes an estimated Six Hundred and Sixty Thousand deaths each year from Two Hundred and Ninteen million cases of illness. Scale-up of WHO recommended malaria control measures has been associated with a Twenty Six Percent reduction in the global malaria death rate over the last decade. Effective malaria vaccines could be an important complement to existing measures, if they can be successfully developed.

 

The new roadmap, launched today at the annual conference of the ASTMH in Washington DC and also announced in a letter published in "The Lancet", aims to identify where additional financing and efforts will be particularly key in developing second generation malaria vaccines both for protection against malaria disease and for malaria elimination. These include next-generation vaccines that target both Plasmodium falciparum and Plasmodium vivax species of malaria.